What is NVCR's current stock price?

NVCR (NovoCure Limited) is currently trading at $17.96 with a market cap of $2.08B.

What sector is NovoCure Limited in?

NovoCure Limited (NVCR) operates in the Healthcare sector, specifically in the Medical - Instruments & Supplies industry.

Is NVCR a good stock to buy?

Analysts have a Buy consensus on NVCR with a price target of $33.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NVCR NovoCure Limited

Healthcare

$17.96+0.34%ClosedMarket Cap: $2.08B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.20

P/S

3.08

EV/EBITDA

-13.87

DCF Value

$-29.47

FCF Yield

-2.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.2%

Operating Margin

-27.2%

Net Margin

-25.7%

ROE

-50.8%

ROA

-22.0%

ROIC

-31.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$174.1M	$-71.1M	$—
Q4 null	$174.3M	$-24.5M	$—
FY null	$655.4M	$-136.2M	$—
Q3 null	$167.2M	$-37.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$33.50

Target (Median)

$33.50

Target Range

$20.00 - $47.00

1 Strong Buy4 Buy2 Hold0 Sell0 Strong Sell

Wells FargoEqual Weight

2026-05-04

Evercore ISI GroupOutperform

2026-05-01

WedbushNeutral

2026-04-16

HC Wainwright & Co.Buy

2026-02-26

WedbushNeutral

2026-01-15

Trading Activity

Insider Trades

View All

VERNON W ANTHONYdirector

SellTue Apr 28

Weinberg Uriofficer: Chf Medical and Innovation Ofr

SellThu Mar 05

Weinberg Uriofficer: Chf Medical and Innovation Ofr

SellThu Mar 05

Weinberg Uriofficer: Chf Medical and Innovation Ofr

SellThu Mar 05

Leupin Nicolasofficer: Former Chief Medical Officer

SellThu Mar 05

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

Exchange

—

Beta

0.90

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Peers

EVO